Tyra Biosciences, Inc. Leases Disclosure

9. Leases

The Company has operating leases for its office and laboratory space, including its corporate headquarters.

In August 2020, the Company entered into a lease agreement for approximately 4,734 square feet of office and lab space at 2656 State Street in Carlsbad, California, for the Company’s headquarters (the Original Lease). The Original Lease commenced in May 2021 and had an original term of 60 months, with an option to extend for two additional 36 month periods.

In March 2022, the Company entered into a lease agreement for approximately 8,331 square feet of additional office and laboratory space at 2676 State Street in Carlsbad, California (the Expansion Lease). The Expansion Lease commenced for accounting purposes in May 2023, when the Company gained access to the premises. The Company’s obligation for payment of base rent began on the date the landlord delivered possession of the Expansion Lease premises in November 2023. The landlord completed improvements to the Expansion Lease premises, and the Company paid $0.5 million toward these costs prior to the Expansion Lease commencement. The Company determined that the landlord is the accounting owner of these improvements, and therefore this payment was included in the measurement of the right-of-use asset and corresponding lease liability. The Company was granted rent abatement for delays related to the landlord’s delivery of the Expansion Lease premises to the Company. The Expansion Lease has a lease term of 120 months, commencing on the day the landlord delivered possession of the Expansion Lease premises. The Company has the option to renew the Expansion Lease for two additional 36-month periods. The Original Lease was also amended to have the same lease expiration as the Expansion Lease.

The Company did not include the renewal periods in determining the lease term, as the Company was not reasonably certain to exercise either the amended Original Lease or the Expansion Lease renewal options.

In connection with the Company’s lease agreements, the Company paid security deposits of $0.1 million and is required to maintain a letter of credit of $1.0 million. The letter of credit may be reduced to $0.9 million in 2027 and further reduced to $0.5 million in 2028.

Cash paid for amounts included in the measurement of lease liabilities was $0.9 million and $0.8 million for the years ended December 31, 2025 and 2024, respectively.

The components of lease expense include operating, short-term, and variable lease costs. Amortization is recorded within research and development and general and administrative expenses in the statements of operations and comprehensive loss. Components of lease cost for the years ended December 31, 2025 and 2024, respectively, were as follows (in thousands):